---
title: 'MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children''s
  Oncology Group Trial AALL1231'
date: '2024-03-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38457359/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240309170617&v=2.18.0.post9+e462414
source: Blood
description: Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains
  a challenge. AALL1231 was a COG phase 3 clinical trial for newly diagnosed with
  T Acute Lymphoblastic leukemia or T-LL patients randomizing children and young adults
  to a modified augmented BFM backbone to receive standard therapy (Arm A) or with
  addition of bortezomib (Arm B). Optional bone marrow (BM) samples to assess minimal
  residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed
  to ...
disable_comments: true
---
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a COG phase 3 clinical trial for newly diagnosed with T Acute Lymphoblastic leukemia or T-LL patients randomizing children and young adults to a modified augmented BFM backbone to receive standard therapy (Arm A) or with addition of bortezomib (Arm B). Optional bone marrow (BM) samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to ...